NB
Nabriva Therapeutics plc
NBRVF · OTC
$0.00 +0.00% (+$0.00)
Market Cap $323.0
P/E Ratio -
Div. Yield -
ROE -
Piotroski F-Score Weak
3/9Valuation
100 /100
Cheap P/B 0.00x
P/S 0.00x
P/FFO N/A
Growth
78 /100
Growing Book val. growth 56.95%
Rev. growth 66.35%
FCF growth N/A
Profitability
6 /100
Weak Op. margin 155.57%
Gross margin 19.87%
FCF margin 103.52%
Quality
20 /100
Poor Asset turnover 1.12x
ROIC 634.43%
ROA 180.03%
Debt
51 /100
Moderate Int. coverage -78.68x
Debt/Equity 1.59x
Net debt/EBITDA 0.13x
Stability
35 /100
Moderate EPS volatility 26.83%
Beta -0.68x
Profitable years 0
Bulios Scoring popisuje kvalitu a minulost firmy, ne budoucí výnos. Vysoké skóre není nákupní signál. Zjistit více
Zeptejte se StockBota na NBRVF
Online
Sector
Healthcare
Industry
Biotechnology
CEO
H. Michael Hogan
Employees
39
Headquarters
Dublin
Nadcházející události
13 LIS
Earnings
Upcoming earnings report